On November 4, 2025, CDR-Life and Boehringer Ingelheim announced a new global licensing agreement to develop CDR-Life’s unique antibody-based molecule CDR111 for autoimmune diseases. The agreement builds on the companies’ successful collaboration on an investigational antibody fragment. Under the terms of the agreement, CDR-Life is eligible for up to a total of CHF 456 m in payments, including CHF 38 m in upfront and near-term payments, plus tiered royalties on future sales.
Homburger acted as counsel to CDR-Life AG. The Homburger team was led by Luca Dal Molin (IP / IT) and included Richard Stäuber (Regulatory) and Joel Fink (IP / IT).